Latest / Boardroom Conversations with Fexingo: CEOs, Strategy, and Corporate Leadership Explained
How Novo Nordisk Built a Board That Balanced Science and Scale
Explore how Novo Nordisk's board navigates the challenge of scaling a blockbuster drug — semaglutide — without losing the company's scientific soul. This episode dives into the unique governance structure that separates the company's charitable foundation from its commercial board, the decision to cap insulin prices at $25 in 2023, and how the board prepared for Ozempic's explosive demand. Lucas and Luna discuss the 'two-tier' system, the tension between patient access and profit, and what other pharma boards can learn from Novo's long-term thinking anchored…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.